No abstract available
MeSH terms
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / economics
-
Dipeptidyl-Peptidase IV Inhibitors / supply & distribution
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Drug Costs
-
Financing, Government
-
Glucagon-Like Peptide 1 / agonists
-
Glycated Hemoglobin / metabolism
-
Health Services Accessibility / economics
-
Healthcare Financing
-
Humans
-
Hypoglycemia / chemically induced
-
Hypoglycemic Agents / economics
-
Hypoglycemic Agents / supply & distribution*
-
Hypoglycemic Agents / therapeutic use
-
New Zealand
-
Practice Guidelines as Topic
-
Sodium-Glucose Transporter 2 Inhibitors
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Sodium-Glucose Transporter 2 Inhibitors
-
hemoglobin A1c protein, human
-
Glucagon-Like Peptide 1